Clinical Trial Detail

NCT ID NCT02453282
Title Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). (MYSTIC)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Durvalumab

Cisplatin + Gemcitabine

Carboplatin + Gemcitabine

Carboplatin + Paclitaxel

Tremelimumab

Durvalumab + Tremelimumab

Cisplatin + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Age Groups: adult senior

Additional content available in CKB BOOST